Zofia Piotrowska, MD


OncView™ Podcast: EGFR Exon 20 Insertion as a Therapeutic Target in NSCLC

In an OncView™ program, Zofia Piotrowska, MD, touched on testing, treatment approaches, and therapeutic options for EGFR exon 20 insertion mutations in non–small cell lung cancer.

Juan Pablo Alderuccio, MD


Oncology Peer Review On-The-Go: Current Treatments in Marginal Zone Lymphoma

Juan Pablo Alderuccio, MD, spoke with CancerNetwork® about a review article on the treatment of marginal zone lymphoma published in the journal ONCOLOGY®.

Surbhi Sidana, M.D.


The Important Role of Cell Therapy in Multiple Myeloma: Three Reasons Why It’s Here to Stay

Dr. Sidana shares insights on how CAR T cell therapy is giving patients with relapsed or refractory multiple myeloma a chance at remission

Ramez Eskander, MD


The Future of Immunotherapy in Low-Grade Serous Ovarian Cancer Treatment

The panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.

Steven Vogl, MD


HER2+ Advanced Breast Cancer: Selecting Third-Line Therapy

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

Andrés Gómez De León, MD


Tandem 2022 Presentation: Haploidentical versus Matched Unrelated Donor Transplants for Lymphomas Using Post-transplant Cyclophosphamide

This article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.

Nirav Patil, MBBS, MPH


The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral Center

COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.

Vinit Makkar, MD


Key Takeaways from the PARADIGM Study

Drs Gupta and Makkar conclude their discussion by highlighting key takeaways from the PARADIGM study and future directions that may address unmet needs in the field of la/mUC.

Trevor J. Pugh, PhD


Trevor J. Pugh, PhD, on Reducing the Burden of Serial Testing for MMRd With 1 Sequencing Protocol

CancerNetwork® sat down with Trevor J. Pugh, PhD, to discuss a novel protocol for detecting mismatch repair deficiency.

Natasha Garg, DO, MS


Toxicity Management in Patients With Multiple Myeloma

Experts explain strategies for toxicity management in patients receiving treatment for multiple myeloma, including monitoring risk of CRS.

Hans Kristian Nugraha, MD, SpOT


An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report

Hans Kristian Nugraha, MD, SpOT, and colleagues detail the potential benefits of an arthroscopic surgical approach through a case study of a patient with giant cell tumor of bone.

Jill S. Barnholtz-Sloan, PhD


The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral Center

COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.

Alan P. Skarbnik, MD, Novant Health Cancer Institute


Relapsed/Refractory CLL: Key Takeaways and Ongoing Challenges

Closing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.

Natasza Posielski, MD


Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017

Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.

Gina Mauro


Mezigdomide Combos Yield Encouraging Responses in R/R Multiple Myeloma

Many patients with relapsed/refractory multiple myeloma appear to remain on treatment with mezigdomide-based regimens for more than 1 year, according to Albert Oriol, PhD.

Mitchell Kamrava, MD


Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

James Masciale, PhD


Decisional Capacity Determination in Patients With Cancer

Experts discuss the process of assessing decision-making capacity in patients with cancer.

Natasha Khrystolubova, BPharm, RPh, BCOP


Expert Commentary on the product profile of Belzutifan for Renal Cell Carcinoma

In an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.

Fernando Peralta-Pizza, MD


Signaling Pathways in the Relapse of Glioblastoma

Javier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Javier I. Altamirano-Garcia, MD


Which Larynx-Preservation Strategy Would Be Best for a Patient With Resectable, Locally Advanced, Hypopharynx Squamous Cell Carcinoma?

A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician’s office. He received empirical treatment with oral antibiotics and experienced partial improvement. A couple of months later, he developed a left cervical mass with progressive growth. A head and neck CT scan revealed a hypopharyngeal tumor. Results of a tumor biopsy indicated an ulcerated, moderately differentiated squamous cell carcinoma (SCC) with lymphovascular invasion. The patient was sent to our institution for treatment.